Table 1 Clinical characteristics of participants

Number, N

28

13

15

15

Age, years

Median

30

58

68

64

Range

23-55

37-82

40-75

34-74

HER2/neu receptor, N (%)

Positive

N.A.

13 (100%)

15 (100%)

0 (0%)

Negative

0 (0%)

0 (0%)

15 (100%)

Estrogen receptor, N (%)

Positive

N.A.

9 (69%)

8 (44%)

11 (70%)

Negative

4 (31%)

7 (46%)

4 (30%)

Progesterone receptor, N (%)

Positive

N.A.

5 (38%)

1 (10%)

7 (40%)

Negative

8 (62%)

14 (90%)

8 (60%)

Trastuzumab, N

N.A.

13 (100%)

15 (100%)

N.A.

Median application time, months

7

58

IQR

5

45

Chemotherapy, N (%)

FEC

N.A.

1 (10%)

1 (10%)

FEC-Doc

1 (10%)

EC

3 (20%)

EC-D

2 (10%)

CMF

1 (10%)

Docetaxel + Epirubicin

3 (20%)

1 (10%)

Docetaxel

1 (10%)

Vinorelbin

1 (10%)

1 (10%)

Carboplatin

1 (10%)

Paclitaxel

1 (10%)